Canbex Therapeutics Ltd
Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new standard in the treatment of spasticity.
The company’s lead compound, VSN16R, is currently in a Phase II study to determine its efficacy in relieving spasticity in people with MS. VSN16R was shown to be safe and well tolerated in a Phase I human safety trial in healthy volunteers that was completed in 2014.
Dr Jesse SchulmanCEO
Censo Biotechnologies Ltd
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.
The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.
By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.
Mr Aidan CourtneyChief Executive Officer
CIMYM BioSciences was established to develop oncology and immunological therapeutics. At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care. CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.
Crescendo Biologics Ltd
Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform.
Fusion Antibodies Ltd
Fusion Antibodies is a high quality European CRO that offers a range of fee-for-service, royalty free technology services covering all stages of therapeutic development of Biopharmaceutical drugs- from discovery/preclinical to cell line development and clinical supply.
Our clients are global Japan, USA & Europe and include Academic, Biotech’s and most of the top 10 pharmaceutical companies.
Four antibodies which have been produced using Fusion Antibodies technologies are currently being progressed through clinical development.
At BioEurope, Fusion Antibodies showcases our next generation CDRx Antibody Humanization Platform (www.fusionantibodies.com/humanization) converting Mouse, Rat, Rabbit and Llama antibodies into high expressing, functional humanized antibody lead drug candidates.
CDRx platform Humanization Key points
• Next generation in silico Antibody Humanization platform
• Improvements over traditional CDR grafting methods
• T-Cell epitope screening and avoidance included in the design stage
• 3D structural predictions included
• No Royalty Fee
• 15 years experience of Antibody drug development
• Humanized variants that can be named with the suffix –“tuzumab” under the International Nonproprietary Names (INN) Programme as governed by the WHO
• Humanized variants selected for manufacturability and expression
• Stable cell expression with CHOvolution cell line capable of up to 7g per litre
• 4 humanized antibodies entering the clinic in 16/17
• More than 60 humanization projects completed worldwide for large pharma, mid-size and biotechs in the past 5 years in Japan, USA & Europe.
We look to partner with companies interested in developing high quality antibody drugs. We also offer a range of cell line development services (https://www.fusionantibodies.com/CLD) and have the associated expertise and partners to deliver a high quality CHO cell line expression for your protein of interest from proof-of-concept to cGMP. Fusion Antibodies also specialize in high quality monoclonal antibodies (particularly those which are difficult to produce), Antibody Sequencing and other Antibody engineering project (scFv, F(ab), Bi-Specifics). We have the capacity to act as a 1-stop shop, guiding your project from discovery to validation in the clinic.
Summary Fusion Antibodies services
cGMP ready CHO cell line development
Manufacture of Biopharmaceuticals for Phase I, II and III clinical studies
With 15+ years of experience in the antibody drug research industry and >60 antibody humanization projects with multiple candidates now in the clinic.
Fusion Antibodies is the 1st choice for accelerating your antibody research towards the clinic.
Let us make your idea a clinical ready drug Asset!
Dr Paul KerrManaging Director
Glythera is an early-stage Biotechnology company focused on the development of next-generation biologics, principally Antibody Drug Conjugates (ADCs) for cancer indications.
The Company’s ADC pipeline is based on an industry-leading, proprietary conjugation platform, ‘PermaLink’, which enables ADCs with higher therapeutic indices – a clear market need in fighting difficult-to-treat tumours. PermaLink is a cysteine-specific, non-maleimide approach that demonstrates significantly improved ADC conjugation stability and improved product homogeneity resulting in improved TI and patient safety profiles. Through PermaLink, Glythera is able to combine novel, highly potent toxins that induce apoptosis with novel antibodies that target cancer-specific antigens, especially those that are highly overexpressed in solid tumours.
The company is currently using its proprietary technology and access to a broad range of toxin payloads to develop a portfolio of class leading ADCs. Glythera is funded by IP Group and the North East Technology Fund and is based in Newcastle Upon Tyne, England.
Dr David SimpsonCEO
Dr Ian EvettsChief Business Officer
Medherant develops transdermal patches using its novel Tepi-Patch® technology. Its unique solvent-free adhesive allows direct dissolution of a wide range of drugs achieving high drug loading, sustained strong drug release and excellent patch adhesion. TepiPatch® can improve upon existing patches or allow development of patches for hard to formulate drugs.
MGB Biopharma Ltd
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.
Mr Raymond SpencerCFO
Mironid Ltd is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer. Mironid is currently building and progressing a pipeline of early stage drug discovery programmes that are initially targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of therapeutic indications in areas of high unmet medical need.
Dr Neil WilkieChief Operating Officer
Nascient Ltd is a funded, privately-held biotech company developing novel therapies for the treatment of inflammatory diseases.
Based in the United Kingdom, Nascient is developing Matriximab, a fully human mAb targeting the Fibrinogen Globe (FBG) of Tenascin C. FBG is a novel therapeutic target involved in the initiation of acute inflammation and the onset of chronic disease.
Nascient is funded by Imperial Innovations.